| References: |
BG45 is an HDAC class I inhibitor with selectivity for HDAC3 (IC50 = 289 nM). It inhibits HDAC1, HDAC2, and HDAC6 with greatly reduced potency (IC50s = 2, 2.2, and >20 µM, respectively). At concentrations up to 50 mg/kg, BG45 alone or in combination with bortezomib has been shown to dose-dependently inhibit tumor growth in a mouse model of multiple myeloma For the detailed information of BG-45, the solubility of BG-45 in water, the solubility of BG-45 in DMSO, the solubility of BG-45 in PBS buffer, the animal experiment (test) of BG-45, the cell expriment (test) of BG-45, the in vivo, in vitro and clinical trial test of BG-45, the EC50, IC50,and affinity,of BG-45, For the detailed information of BG-45, the solubility of BG-45 in water, the solubility of BG-45 in DMSO, the solubility of BG-45 in PBS buffer, the animal experiment (test) of BG-45, the cell expriment (test) of BG-45, the in vivo, in vitro and clinical trial test of BG-45, the EC50, IC50,and affinity,of BG-45, Please contact DC Chemicals. |
